CE-178253

a selective centrally-acting CB1 receptor antagonist; structure in first source

Also Known As:

1-(7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo-(1,5-a)-(1,3,5)triazin-4-yl)-3-ethylaminoazetidine-3-carboxylic acid hydrochloride

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Dyskinesias (Dyskinesia) 04/08/2015 - "Additional benefits provided by cannabinoid related compounds including CE-178253, oleoylethanolamide, nabilone and HU-210 have been reported to possess efficacy against bradykinesia and levodopa-induced dyskinesia in PD. "
2.	Hypokinesia (Bradykinesia) 04/08/2015 - "Additional benefits provided by cannabinoid related compounds including CE-178253, oleoylethanolamide, nabilone and HU-210 have been reported to possess efficacy against bradykinesia and levodopa-induced dyskinesia in PD. "
3.	Weight Loss (Weight Reduction) 08/16/2010 - "Finally, in two preclinical models of obesity, CE-178253 dose-dependently promotes weight loss in diet-induced obese rats and mice. "
4.	Obesity 08/16/2010 - "Finally, in two preclinical models of obesity, CE-178253 dose-dependently promotes weight loss in diet-induced obese rats and mice. "